Navigation Links
Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594 In Patients with Advanced Liver Cancer
Date:7/25/2012

potential to impact both metastatic and primary tumors. In our previously reported randomized Phase 2 dose-ranging study in HCC with intratumoral delivery, we showed a statistically significant benefit in overall survival in the high dose group, which we believe was due, in large part, to the systemic delivery of JX-594 at that dose level."

JX-594: A Multi-Mechanistic Approach To Targeting Cancer

JX-594 is a proprietary, engineered oncolytic immunotherapy designed to selectively target and destroy cancer cells through three diverse mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the shutdown of the blood supply to tumors through vascular targeting and destruction, and 3) the stimulation of the body's immune response against cancer cells, i.e., active immunotherapy. Phase 1 and Phase 2 clinical trials in multiple cancer types to date have shown that JX-594, delivered either directly into tumors or intravenously, induces tumor shrinkage and/or necrosis and is well-tolerated by patients (over 130 treated to date). Objective tumor responses have been demonstrated in a variety of cancers including liver, colon, kidney, lung cancer and melanoma. JX-594 has had a favorable safety profile to date with predictable and generally mild side effects that typically include flu-like symptoms that resolve in 24 to 48 hours.

JX-594 is the most advanced product candidate from Jennerex's proprietary SOLVE™ (Selective Oncolytic Vaccinia Engineering) platform.  SOLVE takes advantage of the natural attributes of poxviruses as well as their potential to be engineered to produce oncolytic immunotherapies that can target and destroy solid tumors both systemically and locally.  The vaccinia poxvirus strain backbone of JX-594 has been used safely in millions of people as part of a worldwide vaccination program. This strain naturally targets cancer cells due to common genetic abnormalities in cancer cells. JX-594 was engin
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex Appoints Dr. Laurent Fischer as President and Chief Executive Officer
2. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
3. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
4. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
5. Misonix Announces New Distribution Agreement For Panama
6. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
9. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
10. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
11. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Pete Rose, baseball,s all-time hits leader, is the ... reliever Myoflex, Ducere Pharma has announced. "Pete,s a ... to have him on board with Myoflex," said Ducere Pharma ... legendary player who is known across all generations. The passion ...
(Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
(Date:1/23/2015)...  Mallinckrodt plc (NYSE: MNK ) announced today ... repurchase program. The open-ended authorization permits the company to ... shares. "Funding additional initiatives and seeking ... continue to pursue a range of focused growth strategies," ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... the World Health Organization warned that a Swine Flu ... firm announced it will host a teleconference for insurance ... seen with everything from asbestos litigation to hurricanes to ... enormously important role in the global economy when disaster ...
... that new cosmeceutical improves skin barrier function, erythema and ... Senetek PLC (OTC Bulletin Board: SNKTY), a ... that target the science of healthy aging, today announced ... for Improving the Signs and Symptoms of Rosacea," has ...
Cached Medicine Technology:Insurance Industry Teleconference on Swine Flu Pandemic Set for May 13 2Spotlight on Rosacea Advance - May Issue of Journal of Drugs in Dermatology Features Pyratine XR(TM) Clinical Study 2
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... has released a new blog post explaining the main features ... , Auto insurance quotes help many drivers find the best ... call an agent or visit an agency for price information. ... http://autocarinsurancebest.com/ . , Every business who relies heavily on ...
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... Boulder, Colorado (PRWEB) January 22, 2015 Four years ... is Queen – which coincided with the marriage of Avasa & ... album, THE ROAD, which is scheduled for release through White Swan ... heartfelt message that there is a sacred path available to all ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 JJsHouse.com is a ... dresses. Today, the business announces its latest collection of ... , “The most important issue is the wedding dress on ... thing in a woman’s life. Every bride wants to find ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... Texas, Nov. 7 Perot Systems,Corporation (NYSE: ... a company it acquired in August 2007, will ... important milestone toward full,integration. Perot Systems will now ... which reflects its ability to access the global ...
... announced today that Immediate Past President and public,health leader ... home outside,East Lansing, Michigan. He was diagnosed with pancreatic ... served as the 162nd,president of the AMA from June ... on,preventive medicine and had been a longtime public health ...
... whose nose has been destroyed by a tumor or injury ... among the most challenging tasks in plastic surgery. Helmut Fischer ... surgery in the current issue of Deutsches rzteblatt International ... authors present the case of a woman who had had ...
... A unique approach to bone marrow transplantation pioneered in ... physician has proven to be the only safe and ... new study. , Lakshmanan Krishnamurti, MD, a pediatric hematologist/oncologist ... marrow transplantation which relies on reduced-intensity conditioning (RIC). RIC ...
... Healthcare,Solutions, Inc. (formerly named Allscripts Healthcare Solutions, Inc.), ... and,headquartered in Chicago, Illinois announced today its offer ... Senior Debentures due 2024 (the,"Debentures") at a purchase ... 100% of the principal amount of the Debentures ...
... 700 health plans evaluated based on quality of ... U.S. News Media Group and The,National Committee for ... of America,s Best Health Plans on USNews.com. Launched ... Americans prepare to,select their healthcare coverage, the 2008 ...
Cached Medicine News:Health News:Perot Systems Announces Name Change of JJWild 2Health News:Perot Systems Announces Name Change of JJWild 3Health News:AMA Immediate Past President Ron Davis Loses Battle With Cancer, Leaves Enduring AMA and Public Health Legacy 2Health News:AMA Immediate Past President Ron Davis Loses Battle With Cancer, Leaves Enduring AMA and Public Health Legacy 3Health News:Children's Hospital study demonstrates how bone marrow transplant can cure sickle cell disease 2Health News:Allscripts Announces Notice of Offer to Purchase in Cash 3.50% Convertible Senior Debentures due 2024 2Health News:Allscripts Announces Notice of Offer to Purchase in Cash 3.50% Convertible Senior Debentures due 2024 3Health News:Allscripts Announces Notice of Offer to Purchase in Cash 3.50% Convertible Senior Debentures due 2024 4Health News:U.S. News Media Group and NCQA Release 2008 Rankings for America's Best Health Plans 2Health News:U.S. News Media Group and NCQA Release 2008 Rankings for America's Best Health Plans 3
Headlight module is mounted on UltraLite Plus sweatband....
The ICP-Monitor for intraventricular, intraparenchymal and epidural measurement of intracranial pressure and for measuring cerebral perfusion pressure and compliance....
It is a fiberoptic based intracranial monitoring systems for continuous monitoring of pressure....
... ICP Monitoring System provides ... intracranial pressure at the ... levels. The information is ... through a hydrostatic column ...
Medicine Products: